By Colin Kellaher
Essa Pharma's stock price plunged after the clinical-stage pharmaceutical company said it was throwing in the towel on its lead product candidate and exploring strategic alternatives.
Shares of the South San Francisco, Calif., company were down 63.5% at $1.90 in premarket trading Friday.
Essa late Thursday said it was ending Phase 2 study of masofaniten in prostate cancer after determining the study was unlikely to meet its primary endpoint.
The company said it would also terminate other studies involving masofaniten and launch a process to review strategic options focused on maximizing shareholder value.
Essa, which had a market capitalization of nearly $231 million based on Thursday's closing price of $5.20, said it had net working capital of $124.3 million as of Sept. 30.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 01, 2024 06:50 ET (10:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。